Journal article · 2025 · Open access

The Superiority of Clozapine Over Second-Generation Antipsychotics in Patients With Treatment-Resistant Schizophrenia: Room for Doubt

Chittaranjan Andrade

The Journal of Clinical Psychiatry, 86(3) · Published 25 August 2025 · DOI 10.4088/jcp.25f16038

Open PDFView at the publisherCite this paper

In brief

“The Superiority of Clozapine Over Second-Generation Antipsychotics in Patients With Treatment-Resistant Schizophrenia: Room for Doubt” is a 2025 journal article by Chittaranjan Andrade, published in The Journal of Clinical Psychiatry. OpenAlex counts 1 citations as of 20 November 2026. It is open access: the full text is free to read at The Journal of Clinical Psychiatry.

Citations
1
Most cited in
2026 (1)
Field-weighted impact
0.43
References
42
Authors
1

Abstract

Schizophrenia is a major mental illness with a median lifetime prevalence, across studies, of 0.5%. Across definitions of treatment resistance, about 37% of schizophrenia patients do not respond to treatment, and about 24% are treatment resistant from the first-episode, itself. Treatment resistance is addressed by trialing different antipsychotics and with antipsychotic augmentation strategies; what augmenting agent is used depends on what the target symptoms are. A landmark study in 1988 demonstrated the efficacy of clozapine in treatment resistant schizophrenia (TRS). Confirmatory studies and meta-analyses followed, establishing clozapine as the drug of choice for TRS in schizophrenia treatment guidelines across the world. Between 2016 and 2025, 2 network meta analyses (NMAs) and 1 individual participant data meta-analysis (IPD-MA) examined randomized controlled trials (RCTs) of clozapine vs other antipsychotics in TRS. The NMAs found that clozapine was superior to first-generation antipsychotics; however, clozapine did not head rankings for overall symptoms, positive symptoms, or negative symptoms, and, in pairwise analyses, there was little difference between clozapine and olanzapine and clozapine and risperidone for overall symptoms, positive symptoms, and negative symptoms. The IPD-MA found that clozapine was no better than comparator second-generation antipsychotics, considered singly or together, for overall symptoms, positive symptoms, and negative symptoms, in the short term, intermediate term, and long term. These findings fly in the face of clinical experience and treatment guideline recommendations. Among possible explanations, notable was that clozapine was significantly superior to comparator drugs when disregarding RCTs sponsored by the manufacturer of olanzapine. Clozapine is associated with many inconveniencing, distressing, and serious adverse effects that may be rare or common. Given the findings that olanzapine and risperidone may be as good as clozapine in TRS, it may be worth trialing these drugs before clozapine in patients with TRS. These and related issues, including nuances, are discussed.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Andrade, C. (2025). The Superiority of Clozapine Over Second-Generation Antipsychotics in Patients With Treatment-Resistant Schizophrenia: Room for Doubt. The Journal of Clinical Psychiatry, 86(3). https://doi.org/10.4088/jcp.25f16038

MLA 9

Andrade, Chittaranjan. “The Superiority of Clozapine Over Second-Generation Antipsychotics in Patients With Treatment-Resistant Schizophrenia: Room for Doubt.” The Journal of Clinical Psychiatry, vol. 86, no. 3, 2025. https://doi.org/10.4088/jcp.25f16038.

Chicago

Andrade, Chittaranjan. 2025. “The Superiority of Clozapine Over Second-Generation Antipsychotics in Patients With Treatment-Resistant Schizophrenia: Room for Doubt.” The Journal of Clinical Psychiatry 86 (3). https://doi.org/10.4088/jcp.25f16038.

Harvard

Andrade, C. (2025) ‘The Superiority of Clozapine Over Second-Generation Antipsychotics in Patients With Treatment-Resistant Schizophrenia: Room for Doubt’, The Journal of Clinical Psychiatry, 86(3). doi:10.4088/jcp.25f16038.

IEEE

C. Andrade, “The Superiority of Clozapine Over Second-Generation Antipsychotics in Patients With Treatment-Resistant Schizophrenia: Room for Doubt,” The Journal of Clinical Psychiatry, vol. 86, no. 3, 2025, doi: 10.4088/jcp.25f16038.

BibTeX

@article{andrade2025superiority,
  title     = {{The Superiority of Clozapine Over Second-Generation Antipsychotics in Patients With Treatment-Resistant Schizophrenia: Room for Doubt}},
  author    = {Andrade, Chittaranjan},
  journal   = {The Journal of Clinical Psychiatry},
  year      = {2025},
  volume    = {86},
  number    = {3},
  doi       = {10.4088/jcp.25f16038},
  url       = {https://doi.org/10.4088/jcp.25f16038}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment

  • clozapine
  • treatment-resistant schizophrenia
  • atypical antipsychotics
  • olanzapine
  • risperidone
  • antipsychotic augmentation
  • network meta-analysis
  • individual patient data meta-analysis

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Andrade, C. (2025). The Superiority of Clozapine Over Second-Generation Antipsychotics in Patients With Treatment-Resistant Schizophrenia: Room for Doubt. The Journal of Clinical Psychiatry, 86(3). https://doi.org/10.4088/jcp.25f16038

How many times has this paper been cited?

1 times, according to OpenAlex on 20 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at The Journal of Clinical Psychiatry: sign in and open the PDF from this page.

Who wrote this paper?

Chittaranjan Andrade.

What is the DOI of this paper?

10.4088/jcp.25f16038, permanently at https://doi.org/10.4088/jcp.25f16038. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 20 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.